FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567138297> ?p ?o ?g. }

• W2567138297 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAMechanism-based pharmacokinetic (PK)/pharmacodynamic (PD) modeling allows us to dissect system-specific and drug-specific effects, and has proven to be a powerful tool for rational human dose projections. While PK/PD modeling has been applied reasonably well to predict the efficacious dose levels of small molecule cytotoxic drugs and antibody-drug conjugates (ADCs), there is no systemic evaluation of methods in predicting human efficacious doses for monoclonal antibodies (mAbs) targeting the signal transduction pathways for oncology indications. We collected reported preclinical and clinical data from 4 mAbs targeting the signal transduction pathways (cetuximab (anti-EGFR), panitumumab(anti-EGFR), onartuzumab(anti-cMET), trastuzumab(anti-HER2)) and 1 anti-angiogenesis mAb (bevacizumab) for anti-cancer therapy. A series of mechanism-based tumor growth/tumor inhibition models were developed using published dose-ranging mouse xenograft PK and PD data. PK parameters for each mAb in tumor-bearing mice were first estimated and were subsequently used to drive the PD parameter estimation for observed tumor growth and growth inhibition using non-linear mixed effects modeling approach by NONMEM (version 7.2, Icon Solutions). The intrinsic tumor exponential and/or linear growth rates (Kg), the extrinsic drug-specific maximum tumor inhibition capacity (Kmax) and the serum drug concentrations needed to achieve half of Kmax (EC50) were obtained by weighted least squares estimation. For all 5 mAbs, the steady-state plasma drug levels in cancer patients associated with clinically efficacious doses were found to fall between the model-predicted mean EC90 and EC95 values for each mAb. Using model-based mouse EC90 and EC95 and human antibody systemic clearance, the predicted clinically efficacious doses for these 5 mAbs were within 2-fold of their efficacious doses demonstrated in cancer patients. Interestingly, using the calculated mouse tumorstatic concentrations based on PK/PD model parameters, the predicted human doses were in general more than two-folds lower compared with clinically efficacious doses. Although tumorstatic concentrations were used to predict the clinical doses of small molecule cytotoxic drugs and ADCs reasonably well, we found that tumoricidal concentrations represented by EC90 and EC95 appear to have a better predictive value for mAbs targeting the signal transduction pathways in oncology. In conclusion, a mechanism-based PK/PD modeling approach was developed to project human efficacious doses for several mAbs in the cancer clinic and it can be used to predict human doses for investigational mAbs in the same class.Citation Format: Songmao Zheng, Honghui Zhou, Weirong Wang. Predicting therapeutic monoclonal antibody efficacious human doses from mouse experimental tumors: a pharmacokinetic/pharmacodynamic approach. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4508. doi:10.1158/1538-7445.AM2015-4508" @default.
• W2567138297 created "2017-01-06" @default.
• W2567138297 creator A5023064904 @default.
• W2567138297 creator A5031629161 @default.
• W2567138297 creator A5041481707 @default.
• W2567138297 date "2015-08-01" @default.
• W2567138297 modified "2023-09-27" @default.
• W2567138297 title "Abstract 4508: Predicting therapeutic monoclonal antibody efficacious human doses from mouse experimental tumors: a pharmacokinetic/pharmacodynamic approach" @default.
• W2567138297 doi "https://doi.org/10.1158/1538-7445.am2015-4508" @default.
• W2567138297 hasPublicationYear "2015" @default.
• W2567138297 type Work @default.
• W2567138297 sameAs 2567138297 @default.
• W2567138297 citedByCount "0" @default.
• W2567138297 crossrefType "proceedings-article" @default.
• W2567138297 hasAuthorship W2567138297A5023064904 @default.
• W2567138297 hasAuthorship W2567138297A5031629161 @default.
• W2567138297 hasAuthorship W2567138297A5041481707 @default.
• W2567138297 hasConcept C111113717 @default.
• W2567138297 hasConcept C112705442 @default.
• W2567138297 hasConcept C121608353 @default.
• W2567138297 hasConcept C126322002 @default.
• W2567138297 hasConcept C159654299 @default.
• W2567138297 hasConcept C203014093 @default.
• W2567138297 hasConcept C2776694085 @default.
• W2567138297 hasConcept C2777802072 @default.
• W2567138297 hasConcept C2779786085 @default.
• W2567138297 hasConcept C2779998722 @default.
• W2567138297 hasConcept C2780035454 @default.
• W2567138297 hasConcept C502942594 @default.
• W2567138297 hasConcept C530470458 @default.
• W2567138297 hasConcept C542903549 @default.
• W2567138297 hasConcept C71924100 @default.
• W2567138297 hasConcept C98274493 @default.
• W2567138297 hasConceptScore W2567138297C111113717 @default.
• W2567138297 hasConceptScore W2567138297C112705442 @default.
• W2567138297 hasConceptScore W2567138297C121608353 @default.
• W2567138297 hasConceptScore W2567138297C126322002 @default.
• W2567138297 hasConceptScore W2567138297C159654299 @default.
• W2567138297 hasConceptScore W2567138297C203014093 @default.
• W2567138297 hasConceptScore W2567138297C2776694085 @default.
• W2567138297 hasConceptScore W2567138297C2777802072 @default.
• W2567138297 hasConceptScore W2567138297C2779786085 @default.
• W2567138297 hasConceptScore W2567138297C2779998722 @default.
• W2567138297 hasConceptScore W2567138297C2780035454 @default.
• W2567138297 hasConceptScore W2567138297C502942594 @default.
• W2567138297 hasConceptScore W2567138297C530470458 @default.
• W2567138297 hasConceptScore W2567138297C542903549 @default.
• W2567138297 hasConceptScore W2567138297C71924100 @default.
• W2567138297 hasConceptScore W2567138297C98274493 @default.
• W2567138297 hasLocation W25671382971 @default.
• W2567138297 hasOpenAccess W2567138297 @default.
• W2567138297 hasPrimaryLocation W25671382971 @default.
• W2567138297 hasRelatedWork W1982518658 @default.
• W2567138297 hasRelatedWork W1995558918 @default.
• W2567138297 hasRelatedWork W2013799896 @default.
• W2567138297 hasRelatedWork W2021534537 @default.
• W2567138297 hasRelatedWork W2048765418 @default.
• W2567138297 hasRelatedWork W2116780606 @default.
• W2567138297 hasRelatedWork W2121831751 @default.
• W2567138297 hasRelatedWork W2561362573 @default.
• W2567138297 hasRelatedWork W2564369413 @default.
• W2567138297 hasRelatedWork W2731322063 @default.
• W2567138297 hasRelatedWork W2753346513 @default.
• W2567138297 hasRelatedWork W2800520776 @default.
• W2567138297 hasRelatedWork W2887286471 @default.
• W2567138297 hasRelatedWork W2981981046 @default.
• W2567138297 hasRelatedWork W2999385409 @default.
• W2567138297 hasRelatedWork W3036212577 @default.
• W2567138297 hasRelatedWork W3083580661 @default.
• W2567138297 hasRelatedWork W3083617143 @default.
• W2567138297 hasRelatedWork W3096508448 @default.
• W2567138297 hasRelatedWork W619211413 @default.
• W2567138297 isParatext "false" @default.
• W2567138297 isRetracted "false" @default.
• W2567138297 magId "2567138297" @default.
• W2567138297 workType "article" @default.